AZD0156: Advancing Selective ATM Kinase Inhibition in Cancer Research

Principle Overview: Targeting the ATM Kinase for Multifaceted Cancer Research

The ataxia telangiectasia mutated (ATM) kinase is a master regulator of the DNA damage response, orchestrating double-strand break (DSB) repair, checkpoint control, and maintenance of genomic stability. Dysregulation or loss of ATM activity is tightly linked to increased genomic instability and tumorigenesis. AZD0156 (CAS: 1821428-35-6) emerges as a next-generation, potent, and selective ATM kinase inhibitor designed to empower cancer research laboratories investigating DNA repair pathways, checkpoint modulation, and metabolic adaptation.

AZD0156 is distinguished by its sub-nanomolar inhibitory potency and exquisite selectivity—demonstrating over 1,000-fold preference for ATM versus other PIKK family members. Its oral bioavailability and robust cellular activity make it ideal for preclinical models. Importantly, the compound not only disrupts canonical DNA repair but also unmasks unique metabolic vulnerabilities, as illuminated in the landmark study ATM inhibition drives metabolic adaptation via induction of macropinocytosis (Huang et al., 2023).

Step-by-Step Workflow: Leveraging AZD0156 in Experimental Protocols

1. Compound Preparation and Handling

• Solubilization: AZD0156 is provided as a solid (purity ≥98%). For in vitro use, dissolve at ≥23.1 mg/mL in DMSO with gentle warming. For ethanol, solubility reaches ≥5.49 mg/mL. The compound is insoluble in water.
• Aliquoting and Storage: Prepare small aliquots and store at -20°C. Use solutions promptly to avoid degradation; avoid repeated freeze-thaw cycles. Long-term storage of solutions is discouraged.
• Quality Control: Each lot is validated by HPLC and NMR. Typical purity exceeds 98%, supporting reproducibility in sensitive kinase assays.

2. Experimental Applications

• In Vitro Assays: Treat cultured cancer cell lines with AZD0156 at concentrations ranging from 10 nM to 1 μM, depending on the sensitivity of the model. For DNA damage response inhibition, pre-treat cells 1–2 hours prior to exposure to DNA-damaging agents (e.g., ionizing radiation or doxorubicin).
• Combination Studies: Combine AZD0156 with DNA double-strand break inducers to assess synthetic lethality or sensitization. For metabolic adaptation studies, co-treat with macropinocytosis inhibitors or nutrient supplementation to dissect cellular survival pathways.
• In Vivo Models: For animal studies, oral dosing is recommended, reflecting AZD0156’s bioavailability. Dosing regimens (e.g., 10–50 mg/kg) should be optimized according to pharmacokinetic and toxicity profiles.

3. Readout and Analysis

• Checkpoint Control: Monitor phosphorylation of ATM substrates (e.g., p53 Ser15, H2AX) via immunoblotting or immunofluorescence.
• DNA Repair Efficacy: Quantify γH2AX foci or comet assays to assess double-strand break accumulation and repair kinetics.
• Metabolic Adaptation: Measure macropinocytosis using fluorescent dextran uptake; analyze amino acid uptake and metabolic flux via LC-MS/MS or NMR-based metabolomics.
• Cell Fate Decisions: Determine proliferation, apoptosis, and clonogenic survival post-treatment.

Advanced Applications and Comparative Advantages

AZD0156 enables breakthrough research at the intersection of DNA repair inhibition and metabolic reprogramming. Unlike generic ATM kinase inhibitors, its high selectivity and oral bioavailability facilitate both in vitro mechanistic studies and in vivo translational experiments—streamlining workflows and minimizing confounding off-target effects.

Recent work by Huang et al. (2023) demonstrated that ATM inhibition by AZD0156 induces macropinocytosis, promoting cancer cell survival under nutrient-poor conditions. Strikingly, combined inhibition of ATM and macropinocytosis suppressed proliferation and induced cell death in both cell culture and animal tumor models. Supplementation with branched-chain amino acids (BCAAs) reversed this effect, highlighting a novel metabolic vulnerability in ATM-inhibited cells. These findings position AZD0156 not only as a selective ATM inhibitor for cancer research, but also as a tool for uncovering metabolic dependencies and designing rational combination therapies.

Comparative analysis with other ATM kinase inhibitors, as discussed in "AZD0156: Unlocking ATM Inhibition for Next-Generation Gen...", underscores AZD0156’s unique chemical structure and >1,000-fold selectivity over related PIKK family enzymes. Its application is further extended in "AZD0156 and the Future of ATM Kinase Inhibition: Mechanis...", where the focus shifts to how AZD0156 bridges DNA damage response inhibition and metabolic adaptation, setting a new benchmark for translational research. For hands-on protocol enhancements, "AZD0156: Selective ATM Kinase Inhibitor for Cancer Research" provides complementary insights into workflow optimization and actionable data interpretation.

Quantitatively, AZD0156 demonstrates sub-nanomolar IC₅₀ in ATM kinase assays and achieves significant checkpoint abrogation at concentrations as low as 30 nM in cellular systems. In preclinical models, oral administration enhances antitumor efficacy of DNA-damaging agents with notable tumor growth inhibition and increased apoptosis.

Troubleshooting and Optimization Tips

• Solubility Issues: If precipitation occurs in DMSO, gently warm and vortex. Avoid diluting directly into aqueous media; instead, prepare intermediate dilutions in ethanol or DMSO before adding to culture media.
• Compound Stability: AZD0156 is stable as a solid at -20°C but degrades in solution over time. Prepare fresh solutions for each experiment and minimize light exposure.
• Cellular Sensitivity: Some cell lines may exhibit variable sensitivity due to inherent differences in ATM pathway activation or compensatory DNA repair mechanisms. Perform titration experiments to identify optimal dosing.
• Off-Target Effects: While AZD0156 is highly selective, high concentrations (>10 μM) may induce cytotoxicity unrelated to ATM inhibition. Validate specificity with genetic ATM knockdown or rescue experiments.
• Metabolic Adaptation Studies: To dissect the interplay between ATM inhibition and nutrient uptake, include controls for macropinocytosis (e.g., EIPA or amiloride derivatives) and metabolite supplementation. Validate uptake using fluorescent tracers and metabolomics.
• In Vivo Dosing: Monitor animal weight, hematological parameters, and organ function to optimize dosing regimens and minimize toxicity.

Future Outlook: Expanding the Horizons of ATM Kinase Inhibition

The unique profile of AZD0156 as a potent ATM kinase inhibitor is catalyzing a paradigm shift in cancer therapy research. Beyond its established role in DNA double-strand break repair and checkpoint control modulation, AZD0156 is revealing previously unappreciated metabolic vulnerabilities—enabling researchers to design rational drug combinations that target both genetic and metabolic drivers of cancer.

Emerging evidence, including from the referenced Huang et al. (2023) study, suggests that integrating ATM inhibition with metabolic modulation could offer new therapeutic windows, particularly in tumors with wild-type p53 or those reliant on nutrient scavenging. As highlighted in "AZD0156 and the Next Frontier: Integrating ATM Kinase Inh...", researchers are now positioned to move beyond conventional DNA repair studies—probing the interplay between genome maintenance and cellular metabolism at unprecedented depth.

As clinical evaluation of AZD0156 progresses, its translational potential will depend on continued innovation in experimental design, biomarker discovery, and combination therapy strategies. The selective, data-driven nature of this ATM kinase inhibitor ensures its continued relevance for next-generation genomic stability regulation, DNA damage response inhibition, and cancer therapy research.

For detailed product specifications, protocols, and ordering information, visit the AZD0156 product page.